Avoro Capital Advisors LLC Has $77.68 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Avoro Capital Advisors LLC lowered its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 3.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,570,000 shares of the biotechnology company’s stock after selling 480,000 shares during the quarter. BioCryst Pharmaceuticals accounts for 1.0% of Avoro Capital Advisors LLC’s holdings, making the stock its 24th biggest position. Avoro Capital Advisors LLC owned approximately 6.09% of BioCryst Pharmaceuticals worth $77,683,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. DRW Securities LLC bought a new stake in shares of BioCryst Pharmaceuticals in the second quarter worth $74,000. XTX Topco Ltd lifted its position in BioCryst Pharmaceuticals by 299.0% during the 2nd quarter. XTX Topco Ltd now owns 156,946 shares of the biotechnology company’s stock worth $970,000 after buying an additional 117,607 shares in the last quarter. Seven Eight Capital LP boosted its stake in shares of BioCryst Pharmaceuticals by 1,407.1% during the 2nd quarter. Seven Eight Capital LP now owns 169,612 shares of the biotechnology company’s stock worth $1,048,000 after buying an additional 158,358 shares during the last quarter. Hsbc Holdings PLC grew its holdings in shares of BioCryst Pharmaceuticals by 32.7% in the 2nd quarter. Hsbc Holdings PLC now owns 125,004 shares of the biotechnology company’s stock valued at $759,000 after acquiring an additional 30,788 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of BioCryst Pharmaceuticals by 896.6% in the second quarter. American Century Companies Inc. now owns 148,490 shares of the biotechnology company’s stock valued at $918,000 after acquiring an additional 133,591 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 6th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Finally, JMP Securities upped their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $14.17.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $8.11 on Monday. The company has a market cap of $1.67 billion, a P/E ratio of -7.58 and a beta of 1.88. The firm’s fifty day moving average price is $7.79 and its two-hundred day moving average price is $6.36. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.11. The company had revenue of $109.30 million during the quarter, compared to analyst estimates of $98.30 million. During the same quarter last year, the company posted ($0.24) EPS. The firm’s quarterly revenue was up 34.9% on a year-over-year basis. As a group, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.45 earnings per share for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.